Investor Relations

AI-driven compound discovery for therapeutics and nutraceuticals.

Vecura, NYB's AI-first compound discovery platform identifies and develops high-potential bioactive compounds faster and with greater precision, then translates them into therapeutic candidates and science-backed nutraceutical products.

Our rigorous approach leverages high-fidelity data, proprietary AI models, and unified workflows, creating a more efficient path to market readiness.

Case Study

By leveraging the Vecura discovery platform for a global consumer health leader, NYB greatly reduced the high costs and long lead times associated with compound discovery for therapeutics and nutraceuticals.

Faster Validation

Compressed discovery cycles to just one month compared to the industry standard of six.

Broader Compound Coverage

Scanned over 700,000 natural compounds, far more than conventional databases. Since then, our natural compound library has grown to over 1.5 million compounds.

64x

Hit Rate

Dramatically improved candidate identification (64%) compared with traditional screening approaches (1%).

Lead Asset Spotlight

NB-A002

Targeting DNA Repair Vulnerabilities in Cancer

NB-A002 is a potentially first-in-class therapeutic candidate designed to address a critical gap in oncology treatment.

The Challenge

DNA damage response (DDR), especially homologous recombination (HRD) positive cancers often develop resistance to standard therapies such as PARP inhibitors and platinum-based chemotherapy, leading to limited treatment options and poor patient outcomes.

NB-A002 targets the previously undruggable ILF2 protein, leveraging a novel mechanism to induce synthetic lethality through transcription–replication conflicts.

This enables

Selective targeting of DNA damage response (DDR)-deficient cancers
A differentiated strategy beyond existing PARP-based approaches
Potential application across multiple oncology indications

Note: NYB assigned the full ownership of Singapore provisional patents for drug candidates. Patents pending in key markets such as the U.S. EU, China and Japan.

Learn More

Strategic Milestone

Nasdaq listing Initiated

NYB has entered into a business combination agreement with RF Acquisition Corp. II as part of its strategy to pursue a Nasdaq public listing.The transaction values NYB at approximately US$1.5 billion.

Investment proceeds will enable NYB to continue its drug discovery in cancer, cardiovascular disease (CVD), obesity and other diseases.

NYB Reflects on NVIDIA GTC 2026: A Week of Discovery, Dialogue, and Momentum

NYB at GTC 2026 with valuable scientific exchange, external feedback, and cross-sector dialogue.

NYB to Exhibit at NVIDIA GTC 2026

NYB is pleased to announce that we will be exhibiting at NVIDIA GTC 2026, taking place from March 16–19, 2026.

NYB Announces $1.5 Billion Business Combination with RF Acquisition Corp II to Pursue Nasdaq Listing

NYB announced a business combination agreement with RF Acquisition Corp II to pursue a Nasdaq listing.

View All